Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

/in , /by

January 5, 2023

Read more

Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors

/in , /by

November 8, 2022

Read more

Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting

/in , /by

March 9, 2022

Read more